Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,188 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,266 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07293468 | Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)(BIIRTH) | recruiting | Phase 2 / Phase 3 | 106 | Tuen Mun HospitalOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06431490 | A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer | recruiting | Phase 1 / Phase 2 | 102 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 |
| Apr 8, 2026 |
| clinicaltrials |
| NCT04906434 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 200 | Abbisko Therapeutics Co, LtdINDUSTRY | 3 | Apr 7, 2026 | clinicaltrials |
| NCT05003895 | GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies | recruiting | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06910722 | Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After SIRT and Chemotherapy(RIS-TH) | recruiting | N/A | 36 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06125769 | LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA)(LITALHICA) | recruiting | N/A | 50 | Azienda Sanitaria OspedalieraOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07107750 | Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer | recruiting | Phase 1 | 48 | Washington University School of MedicineOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05733598 | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | recruiting | Phase 2 | 60 | Replimune, Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06553885 | Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC | recruiting | Phase 2 | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07450976 | A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer | recruiting | Phase 2 | 151 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07504367 | Large Language Models Assist in Tumor MDT | recruiting | N/A | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07312292 | Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)(RADIANT) | recruiting | Phase 2 | 15 | Niek WijnenOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07500220 | Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC(DUET-HCC) | recruiting | Phase 1 / Phase 2 | 30 | Beijing BiotechINDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06687941 | A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors | recruiting | Phase 1 | 70 | Aptamer Sciences, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07331883 | Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2) | recruiting | Phase 2 | 35 | Ruijin HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07495215 | A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection | recruiting | Phase 1 / Phase 2 | 20 | Yinghua XuOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05024214 | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06447064 | Cancer Loyalty Card Study 2 (CLOCS-2)((CLOCS-2)) | recruiting | — | 2,900 | Imperial College LondonOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05849480 | A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) | recruiting | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07392541 | Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer | recruiting | Phase 1 / Phase 2 | 29 | Tongji HospitalOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07466602 | cfDNA Methylation for Liver Cancer Recurrence Detection | recruiting | — | 500 | Wuhan Ammunition Life-tech Co., LtdINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05128890 | Evaluation of Resection Techniques for Pancreatic Tumors | recruiting | — | 431 | Methodist Health SystemOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06140134 | Liver Transplantation in Intrahepatic Cholangiocarcinoma | recruiting | — | 30 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06345508 | Early Detection of Liver Cancer by QUS(QUS in HCC) | recruiting | — | 328 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05629845 | Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients(EUS-SPV) | recruiting | N/A | 84 | Chinese University of Hong KongOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07482059 | A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 33 | West China HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05556642 | Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative | recruiting | — | 500 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06077591 | Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors(PDO) | recruiting | N/A | 40 | Chinese University of Hong KongOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06648057 | Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab | recruiting | — | 100 | CHA UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07142226 | Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC | recruiting | — | 200 | CHA UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07151118 | ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer | recruiting | — | 100 | CHA UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05528952 | Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma(TERTIO) | recruiting | Phase 2 | 105 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07052253 | A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. | recruiting | Phase 2 | 100 | AkesoINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07473687 | Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room(IBPM) | recruiting | — | 315 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05901519 | A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma | recruiting | Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06681233 | Feasibility Study of CBCT for IGRT in Cancer Patients | recruiting | N/A | 50 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05095714 | FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer.(FASTRAK) | recruiting | N/A | 944 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06537193 | Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment | recruiting | N/A | 455 | Asan Medical CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04792463 | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome | recruiting | — | 500 | Mohamed Abdel-RahmanOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06859684 | Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)(HAIC-quad) | recruiting | Phase 2 | 25 | West China HospitalOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04075305 | The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study(MOMENTUM) | recruiting | — | 8,000 | UMC UtrechtOTHER | 9 | Mar 5, 2026 | clinicaltrials |
| NCT04900818 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 330 | I-Mab Biopharma US LimitedINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT06530251 | A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) | recruiting | Phase 1 / Phase 2 | 280 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06885879 | Impact of Radiotherapy on ctDNA in Patients With Hepatocellular Carcinoma | recruiting | — | 15 | Chinese University of Hong KongOTHER | 1 | Mar 4, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 9, 2026source: clinicaltrials